ARS Pharmaceuticals, Inc. SPRY Q1 2025 earnings
Reported May 14, 2025 · Before market open
Revenue estimate$14.7M
EPS estimate-$0.35
Next report
Aug 12, 2026 (in a month)Revenue estimate$31.3M
EPS estimate-$0.48
Financials
Q1 2025Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
Ask the moment ARS Pharmaceuticals, Inc. reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did ARS Pharmaceuticals, Inc. report Q1 2025 earnings?
- ARS Pharmaceuticals, Inc. (SPRY) reported Q1 2025 earnings on May 14, 2025 before market open.
- What were ARS Pharmaceuticals, Inc.'s Q1 2025 revenue and EPS?
- ARS Pharmaceuticals, Inc. reported revenue of $8.0M and diluted EPS of $-0.35 for Q1 2025.
- Did ARS Pharmaceuticals, Inc. beat estimates in Q1 2025?
- Revenue missed the consensus estimate of $14.7M by $6.7M. EPS beat the consensus estimate of $-0.35 by $0.00.
- How did ARS Pharmaceuticals, Inc.'s Q1 2025 results compare year-over-year?
- Compared to the same quarter a year prior, diluted EPS declined 218.2% from $-0.11.
- Where can I find ARS Pharmaceuticals, Inc.'s Q1 2025 SEC filings?
- You can read the 10-Q periodic report (0000950170-25-070900) directly on SEC EDGAR. The filing index links above go to sec.gov.